Literature DB >> 18706829

Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.

Gijsberta J van Londen1, Matthew E Levy, Subashan Perera, Joel B Nelson, Susan L Greenspan.   

Abstract

BACKGROUND: Little is known about the long-term impact of androgen deprivation therapy (ADT) on body composition in men with prostate cancer. We compared body composition parameters in men with non-metastatic prostate cancer on or not on therapy with healthy, age-matched controls at baseline and monitored changes over a 2-year period.
METHODS: We measured body fat mass and lean body mass in 81 men with prostate cancer on no ADT, 43 men on acute ADT (less than 6 months), 67 men on chronic ADT (more than 6 months) and 53 age-matched healthy controls. Measurements were performed every 6 months for 2 years.
RESULTS: Men with prostate cancer on acute ADT (mean 3 months) had significant gains in body fat mass [1499.56+/-322.28g (mean+/-S.E.) after 12 months, 2167.15+/-676.45g after 24 months, p<0.01 for both] and losses in lean body mass (929.74+/-296.36g after 12 months, 1785.81+/-501.31g after 24 months, p<0.01 for both) over 2 years. Men on chronic ADT (mean 31 months) had smaller but still significant body composition changes over 24 months. Changes in body composition in men on no ADT were small and healthy controls had no significant changes.
CONCLUSIONS: Men with prostate cancer on ADT have significant gains in body fat mass and losses lean body mass over 2 years. These changes are most pronounced with initiation of ADT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706829      PMCID: PMC2826163          DOI: 10.1016/j.critrevonc.2008.06.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  29 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

Authors:  Zhao Chen; Michael Maricic; Paul Nguyen; Frederick R Ahmann; Roberta Bruhn; Bruce L Dalkin
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

3.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

Authors:  S A Stoch; R A Parker; L Chen; G Bubley; Y J Ko; A Vincelette; S L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

4.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

5.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Changes in body composition during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

7.  National practice patterns and time trends in androgen ablation for localized prostate cancer.

Authors:  Matthew R Cooperberg; Gary D Grossfeld; Deborah P Lubeck; Peter R Carroll
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

8.  Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

9.  Long-term effects of androgen deprivation therapy in prostate cancer patients.

Authors:  Shehzad Basaria; John Lieb; Alice M Tang; Theodore DeWeese; Michael Carducci; Mario Eisenberger; Adrian S Dobs
Journal:  Clin Endocrinol (Oxf)       Date:  2002-06       Impact factor: 3.478

10.  Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.

Authors:  Jari A Laukkanen; David E Laaksonen; Leo Niskanen; Eero Pukkala; Anna Hakkarainen; Jukka T Salonen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-10       Impact factor: 4.254

View more
  31 in total

1.  Sarcopenia during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 2.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 3.  Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.

Authors:  Lauren Collins; Shehzad Basaria
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

Review 4.  Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.

Authors:  L Collins; N Mohammed; T Ahmad; S Basaria
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

5.  Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy.

Authors:  M Roch; A Zapatero; P Castro; D Büchser; L Pérez; D Hernández; C Ansón; M Chevalier; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2018-10-17       Impact factor: 3.405

6.  Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.

Authors:  J Uth; T Hornstrup; J F Christensen; K B Christensen; N R Jørgensen; J F Schmidt; K Brasso; M D Jakobsen; E Sundstrup; L L Andersen; M Rørth; J Midtgaard; P Krustrup; E W Helge
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

7.  Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors.

Authors:  Gregory P Beehler; Michael Wade; Borah Kim; Lynn Steinbrenner; Laura O Wray
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

Review 8.  The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis.

Authors:  Farhana Haseen; Liam J Murray; Chris R Cardwell; Joe M O'Sullivan; Marie M Cantwell
Journal:  J Cancer Surviv       Date:  2010-01-21       Impact factor: 4.442

Review 9.  The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Authors:  Peter Busch Østergren; Caroline Kistorp; Finn Noe Bennedbæk; Jens Faber; Jens Sønksen; Mikkel Fode
Journal:  Nat Rev Urol       Date:  2016-04-26       Impact factor: 14.432

10.  Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy.

Authors:  Cristiana Reis; Sami Liberman; Antonio Carlos Pompeo; Miguel Srougi; Alfredo Halpern; Wilson Jacob Filho
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.